EVLO (EVLO) Stock Price & Analysis
EVLO (EVLO) rose 0.00% to USD 0 as of June 10, 2026 at 02:16 UTC, according to Nexqual real-time market data.
EVLO last closed at USD 0; the session ranged USD 0–0 on volume of 133 shares. Market capitalization is $1,898, with a 52-week range of USD 0–0 (PNK). Source: Nexqual, June 10, 2026 at 02:16 UTC.
Key Statistics (as of June 10, 2026 at 02:16 UTC)
| Price | USD 0 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 0 |
| Open | USD 0 |
| Day Range | USD 0 – 0 |
| 52-Week Range | USD 0 – 0 |
| Volume | 133 shares |
| Market Cap | $1,898 |
| Exchange | PNK |
Technical Analysis (EVLO)
Nexqual's technical model rates EVLO "BUY" based on 4 bullish and 2 bearish signals across 124 daily candles, as of June 10, 2026 at 02:16 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 100 (overbought) |
| vs SMA50 | Below (USD 0) |
| MACD | 0 (negative) |
Analyst Ratings (EVLO)
Wall Street analysts rate EVLO "None", per Nexqual as of June 10, 2026 at 02:16 UTC.
| Consensus Rating | None |
|---|
Earnings (EVLO)
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2023-09-30 | USD -0.52 vs est -1.17 ▲ beat |
| 2023-06-30 | USD -3.07 vs est -3.81 ▲ beat |
| 2022-12-31 | USD -2.83 vs est -5.5 ▲ beat |
Source: Nexqual, June 10, 2026 at 02:16 UTC.
Financials & Fundamentals (EVLO)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| Current Ratio | 0.48 |
| Total Cash | $17.26M |
| Total Debt | $33.95M |
| Free Cash Flow | $-43.31M |
Source: Nexqual, June 10, 2026 at 02:16 UTC.
Financial Health Score (EVLO)
Nexqual rates EVLO's overall financial health "Weak" across five dimensions, as of June 10, 2026 at 02:16 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — $17M cash vs $34M debt |
| Cash Flow | Weak — Operating cash flow -$74M |
| Efficiency | Mixed — No data |
Ownership (EVLO)
| Insider Ownership | +0.00% |
|---|---|
| Institutional Ownership | +0.00% |
| Shares Outstanding | 18.98M |
| Float | 18.90M |
| Short % of Float | +2.22% |
Source: Nexqual, June 10, 2026 at 02:16 UTC.
Leadership (EVLO)
EVLO is led by Craig R. Jalbert CIRA (age 63), President, Secretary, Principal Executive, Financial and Accounting Officer & Director, per Nexqual as of June 10, 2026 at 02:16 UTC.
| President, Secretary, Principal Executive, Financial and Accounting Officer & Director | Craig R. Jalbert CIRA (age 63) |
|---|---|
| Senior Director & Immunology Clinical Lead | Douglas Maslin |
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| KLDO | Kaleido Biosciences, Inc. | USD 0 | ▲ 0% |
| RUBY | Rubius Therapeutics, Inc. | USD 0 | ▲ 0% |
| ELOX | Eloxx Pharmaceuticals, Inc. Common Stock | USD 11.01 | ▲ 77.58% |
| ARDS | Aridis Pharmaceuticals Inc. | USD 0 | ▲ 0% |
| ATXI | Avenue Therapeutics, Inc. | USD 0.36 | ▲ 2.27% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 02:16 UTC. This page is informational and not investment advice.